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There is increasing interest in circulating tumor cells (CTCs) due to their purported role in
breast cancer metastasis, and their potential as a “liquid biopsy” tool in breast cancer diag-
nosis and management. There are, however, questions with regards to the reliability and
consistency of CTC detection and to the relationship between CTCs and prognosis, which
is limiting their clinical utility.There is increasing acceptance that the ability of CTCs to alter
from an epithelial to mesenchymal phenotype plays an important role in determining the
metastatic potential of these cells. This review examines the phenotypic and genetic vari-
ation, which has been reported within CTC populations. Importantly, we discuss how the
detection and characterization of CTCs provides additional and often differing information
from that obtained from the primary tumor, and how this may be utilized in determining
prognosis and treatment options. It has been shown for example that hormone receptor
status often differs between the primary tumor and CTCs, which may help to explain failure
of endocrine treatment. We examine how CTC status may introduce alternative treatment
options and also how they may be used to monitor treatment. Finally, we discuss the most
interesting current clinical trials involving CTC analysis and note further research that is
required before the breast cancer “liquid biopsy” can be realized.
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INTRODUCTION
Breast cancer is the most common cause of cancer death among
women (1). Prognosis for most patients with early breast cancer
(EBC) is generally very good, however, a significant proportion
(20–30%) of chemotherapy-treated EBC patients relapse with
metastatic disease (2). How to identify those breast cancer patients
who will relapse in the future and develop metastatic disease
remains elusive. Metastatic disease is initiated by circulating tumor
cells (CTCs) that originate from the primary tumor and spread the
cancer in the body via the blood circulatory system. These CTCs
may migrate to, and remain dormant in, sites such as bone mar-
row as disseminated tumor cells (DTCs). After variable latency
periods, DTCs may develop into overt metastases and although
this is not seen in all patients, it is seen more frequently in breast
cancer patients with persistent DTCs (3). Although considerable
research has been conducted to characterize these cells and their
role in dissemination, dormancy, and formation of metastasis,
many questions remain. For example, why are CTCs not detectable
in some patients with metastases, and why is it that some patients
with detectable CTCs never develop metastases?
In a rat model, human mammary tumors have been shown to
shed 3.2–4.1× 106 cells per day per gram of tissue (4), most of
which (~85%) are destroyed within minutes in the circulation (5)
by anoikis, a form of apoptosis driven by loss of cell–cell inter-
actions (6). However, some cells are resistant to anoikis (5). In a
mouse model, approximately 2.5% of CTCs formed micrometas-
tases (most of which subsequently disappeared over time) and
0.01% of CTCs progressed to form macrometastases (7). Metasta-
tic potential is not only influenced by CTCs resistance to anoikis,
but also the ability of CTCs to change their cellular phenotype
from epithelial to mesenchymal – termed epithelial–mesenchymal
plasticity (8).
Detection of either CTCs or DTCs is commonly associated with
an increased risk of metastases and accompanying poor prognosis
(9, 10). Researchers have, however, reported considerable varia-
tion in CTC detection rates and correlation with prognosis, even
in patients with substantial metastatic disease (11). To date, this
has prevented the use of CTCs as a routine prognostic clinical tool
(12). We focus our review on CTCs, their role in breast cancer
progression, and how CTC molecular variation and epithelial–
mesenchymal transition (EMT) may explain discrepancies in CTC
detection, therapy response, and relationship to prognosis.
CTC CHARACTERISTICS
Circulating tumor cells are extremely rare, with a frequency of
typically 1 per 106–7 leukocytes (13). Defining characteristics to
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delineate CTCs from other blood cells is difficult due to the sub-
stantial pleomorphism CTCs exhibit (14). Breast cancer CTCs have
a mean diameter of 13.1µm (15), which is only slightly larger than
blood leukocytes measured at 10µm (16). Accepted CTC charac-
teristics include presence of a nucleus, visible cytoplasm, and the
expression of cytokeratin and absence of CD45 expression (17).
Clusters of CTCs, also called tumor microemboli, are found in
some patients, comprising 4% of CTCs analyzed in one study (14)
and have been demonstrated to form prior to entering the circu-
lation, and to be precursors with more malignant potential than
their unicellular counterparts (18). Cluster presence, particularly
if sustained through treatment, correlates more strongly with poor
prognosis than single CTCs do in metastatic breast cancer (MBC)
patients (18).
EPITHELIAL–MESENCHYMAL TRANSITION
Most breast cancers are of epithelial origin (19). Epithelial cells col-
lectively maintain organized tissue architecture through distinct
contact between cells facilitated by E-cadherin, a homotypic trans-
membrane cell–cell adhesion protein (20, 21). A critical step in
tumor invasion and metastasis is the phenotypical change known
as EMT, normally a highly regulated process involved in embryo-
genesis and wound healing, and implicated in several disease states
including malignancy and fibrosis (22). Physiologically, activation
of a range of highly controlled signaling molecules triggers EMT
in response to specific stimuli (23). However in cancer cells, acti-
vation of this process is dysregulated (22). During EMT, adhesion
molecule expression is altered and cells take on mesenchymal char-
acteristics, becoming more elongated, flexible, mobile, and thereby
potentially invasive (19). This phenotype also mediates increased
resistance to common anti-cancer therapies including taxanes and
anthracyclines (24) and is elevated in breast cancer tissues remain-
ing after neoadjuvant therapies (25). Tumor cells surviving in the
hostile environment of the blood have undergone demonstrated
EMT changes (26, 27), which are considered crucial to the metasta-
tic process (28) and to resistance to anoikis (29). EMT is, for
instance, most evident in “triple-negative” tumors [those without
estrogen receptors (ER), progesterone receptors (PR), and human
epidermal growth factor receptor 2 (HER2)] and HER2 positive
(HER2+) tumors, and least frequent in ER positive (ER+) tumors,
particularly lobular cancers, mirroring the metastatic potential of
these tumor types (27, 30).
Whilst EMT/mesenchymal markers have been demonstrated
on CTCs, breast cancer metastases in liver, lung, and brain often
express higher levels of E-cadherin and hence are often “more
epithelial” than the primary tumor, indicating a reversal of the
EMT process (31), termed mesenchymal to epithelial transition
(MET). Evidence for the importance of this reverse transition and
its role in metastasis is growing rapidly (32–36).
SUB-POPULATIONS OF CTCs
Circulating tumor cells can exist in intermediate states – sub-
populations expressing both epithelial and mesenchymal markers
to varying degrees (27, 37–40). This is likely to be considerably
more common than complete polarization to either state (41).
Sub-populations of tumor cells at any point may also acquire can-
cer “stem-cell” (CSC) attributes such as quiescence, self-renewal,
asymmetric division, drug resistance (38, 42), and resistance to
radiation (43), facilitating survival in the circulation and resul-
tant metastasis. Breast CSCs are most commonly identified with
a CD44+/CD24− phenotype (44) or by the expression of alde-
hyde dehydrogenase 1 (ALDH1) (45). These CSC markers have
been identified in breast cancer CTCs populations by a number of
researchers (46–49).
CTC ISOLATION METHODOLOGIES
Current CTC detection methods rely on CTC physical properties
(e.g., size, density, electric charge, and cell deformability) or on
the retained expression of surface proteins (predominantly epithe-
lial) or messenger RNA. Although there are currently numerous
CTC detection methodologies [comprehensive reviews (13, 50–
53), the CellSearch system (Veridex, USA)], an immunomagnetic
bead capture system based on epithelial cell adhesion molecule
(EpCAM), followed by immunofluorescence analysis predomi-
nates, as it is the only current method to achieve Federal Drug
Administration approval. As malignant cell transcriptional profiles
vary, especially during processes such as EMT and CSC formation,
expression of identifying proteins may be lost in CTCs as well as
being present in non-CTCs, reducing sensitivity and specificity.
Barriere et al. (54) reviewed studies exploring CTC isolation, not-
ing their propensity to co-express epithelial, mesenchymal, and
CSC markers, and recommended development of a combined
isolation method targeting all three phenotypes to avoid missing
clinically relevant CTC sub-populations.
CTCs AS PROGNOSTIC TOOLS
Both CTCs and DTCs have been detected in breast cancer patients
with disease states ranging from ductal carcinoma in situ to MBC
(55–60), and their detection is generally associated with a poor
prognosis. Although CTCs are not seen in all MBC, this may
be due to the inability of current methods to detect EMT sub-
populations (54, 61, 62). Extensive studies in MBC show that
CTCs associate with disease progression (57, 63, 64) with a meta-
analysis by Zhang et al. (10) confirming CTC presence to be an
independent prognostic factor for overall survival (OS) in MBC
(HR= 2.33, p< 0.005).
Links with CTC presence and prognosis in EBC are also sug-
gested (65, 66). Confirming this, a defining meta-analysis by Zhang
et al. (10) showed the presence of CTCs to be an independent
prognostic factor for OS in EBC (HR= 2.78, p< 0.005).
The association of CTCs and prognosis in EBC appears inde-
pendent of tumor grade, histological type, degree of nodal involve-
ment, lymphovascular invasion, or Ki-67 (proliferation marker)
status (67, 68). Mixed results have been seen when considering
receptor-defined breast cancer subtypes. Detection of CTCs is
prognostic in EBC patients with “triple-negative” tumors or ER
negative (ER−) PR negative (PR−) HER2+ primary tumors, but
not in patients with ER+ tumors (69). In contrast, Giordano et al.
(70) found CTCs to be prognostic in all MBC disease subtypes
except HER2+ tumors, whilst Liu et al. (71) found the contrary.
The prognostic importance of CTCs over long-term follow-
up has not been established. CTCs have been detected in patients
in prolonged remission with 36% of patients in one study having
detectable CTCs 8–22 years out from treatment of EBC, despite no
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clinical evidence of disease (72). What proportion of these patients
will go on to develop metastatic disease is not known, nor have the
beneficial effects of CTC-guided intervention been established (see
Monitoring Treatment – Clinical Utility section below).
RECEPTOR DISCORDANCE
Amplification of the HER2/neu gene and subsequent HER2
protein overexpression is associated with significantly decreased
disease-free survival (DFS) and OS in the absence of HER2-
targeted therapy (73, 74). Similarly, patients with HER2+ CTCs
have been reported to have worse progression-free survival (PFS)
and OS in comparison with patients with HER2− CTCs or any
detectable CTCs (75–77). Heterogeneous amplification of HER2
is, however, known to occur within tumors and this serves to con-
found HER2 diagnostics and studies of receptor discordance (78).
Receptor discordance refers to differences in receptors of primary
tumor and metastatic tumors or CTCs. Discordance in HER2 sta-
tus between primary tumor and CTCs reports are variable, in the
order of 15–35% in MBC (75, 79, 80). HER2 discordance has also
been reported in EBC patients. Wulfing et al. (77) found that,
in EBC patients with detectable CTCs, 12 of 24 (50%) patients
with HER2− primary tumors had HER2+ CTCs, and 1 of 3
(33%) patients with HER2+ primary tumors had HER2− CTCs.
A few studies have shown that trastuzumab treatment is effective in
eliminating HER2+ CTCs, including from patients with HER2−
primary tumors and significantly reduced the risk of relapse and
prolonged the DFS (81, 82).
Clinical trials are underway testing the utility of CTCs as a
therapy decision-making tool in such cases of observed discrep-
ancy in HER2 positivity between the primary tumor and CTCs.
The DETECT III trial is randomizing HER2−MBC patients with
HER2+ CTCs to standard therapy with or without lapatinib,
a HER2-targeted therapy. The TREAT-CTC trial is randomiz-
ing HER2− EBC patients with detectable HER2+ CTCs post-
neoadjuvant therapy (NT) and surgery to either standard care or
additional trastuzumab. These studies may provide a foundation
for the use of CTCs in standard clinical practice to identify patients
who may benefit from the addition of HER2−directed therapy.
Discordance between the ER and/or PR status of primary and
metastatic tumors has long been observed (83–85). Given the
role of CTC in progression to metastases, it is not surprising
that the hormone receptor status of CTCs may also differ from
that of the primary tumor. Interestingly, this discordance appears
much greater than that seen between primary and metastatic tis-
sue, implying that receptors may be lost then regained once overt
metastases form. Aktas et al. (86) found that discordance rates
between primary tumor and CTCs for ER and PR in MBC patients
were 59% and 55%, respectively, with most CTCs being ER− and
PR− (84% and 92%). Fehm et al. found discordance rates between
primary tumors and CTCs in EBC for ER and PR to be 71%
and 75%, respectively (87) and HER2 discordance rates in MBC
patients to be 36% (76). Although this suggests that hormone
receptor loss may often be a transient phenomenon connected with
the CTC state, this “sanctuary phenotype” could still contribute to
endocrine therapy failure.
As with HER2 discordance; there are also implications for treat-
ment of ER+ CTCs where the primary tumor is ER−. It remains
to be seen if estrogen-targeted treatments in ER− primary tumors
with ER+ CTCs have a therapeutic effect.
MONITORING TREATMENT – CLINICAL UTILITY
Another important clinical area uses CTCs as an early marker of
disease progression or treatment failure – potentially giving an
indication of a need for change of therapy before conventional
imaging and/or tumor markers demonstrate progression. The lack
of a reliable method to monitor the effects of adjuvant systemic
therapy in particular is a significant area of need. Multiple studies
have shown that in EBC, locally advanced breast cancer, and MBC,
detection of CTCs after the completion of treatment is a strong
prognostic marker (58, 64, 88–90).
Circulating tumor cell changes in MBC response to treatment
can yield important prognostic information. For instance, MBC
patients in whom initially high CTC counts reduced to low lev-
els after initial therapy, had identical prognosis to CTC-negative
patients (64). Correlations between the changes in CTC numbers
and an objective response to therapy as assessed by serial imag-
ing were reported by a study conducted by Nakamura et al. (91).
Pachmann et al. (92) showed that patients who had higher CTC
numbers that declined following treatment had a better prognosis
than those whose CTC count did not change. Utilizing this para-
digm, the SWOG SO500 trial evaluated switching therapy in MBC
patients after one treatment cycle if certain CTC fall thresholds
were not met. This trial did not demonstrate that an early switch
improved DFS or OS, but presence of CTCs was an adverse prog-
nostic factor (93). It has been suggested that the reason for the
failure of this trial to observe a benefit to switching treatment on
the basis of CTC levels is due to the fact that breast cancers with
acquired chemo-resistance to one agent rarely exhibit high sen-
sitivity to a randomly chosen alternative chemotherapeutic agent
(94).
There are a number of ongoing clinical trials examining the
utility of CTCs in breast cancer treatment. Details of some of
the interventional studies employing CTC assessments, which are
currently being run, are shown in Table 1. Results are eagerly
awaited from the CirCe01 trial, which has similar design to the
SWOG SO500 trial but evaluates CTCs serially after each cycle,
with patients in the intervention arm changing therapy if CTC
counts are adverse (see Table 1). Currently, we do not have clinical
trial results supporting the use of CTCs to guide clinical decisions.
Bardia et al. (94) highlighted the need for future clinical trials to
utilize CTC isolation methodologies that are able to isolate CTCs
which have undergone EMT, and to genotype CTCs in order to
evaluate therapeutic response and guide therapeutic choices.
Circulating tumor cells have been studied with respect to their
potential to inform patient therapy. Pierga et al. (95) found a
significant correlation between CTC detection before NT and
reduced DFS, but no correlation between the persistence of CTCs
post-NT and tumor response. Boutrus et al. (96) also found that
CTC presence predicted local and distant relapse, but did not cor-
relate with primary tumor volume reduction. Similarly, Riethdorf
et al. (68) showed that CTC detection before NT did not correlate
with tumor response to treatment, nor did CTC changes necessar-
ily mirror treatment response. This suggests differential responses
to treatment between the primary tumor and CTCs.
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Table 1 | A selection of current ongoing clinical trials examining the clinical utility of circulating tumor cells in breast cancer treatment.
Trial name
(ClinicalTrial.gov
registry number)
Rationale Patient group Methodology Estimated accrual
completion date
CTC-EMT
(NCT02025413)
Evaluating a novel
mesenchymal-marker-based ferrofluid
(N-cadherin or O-cadherin based) CTC
capture method.
Metastatic prostate
or MBC patients
Non-randomized study to evaluate novel
CTC capture method.
December 2014
STIC CTC
METABREAST
(NCT01710605)
Evaluating the medico-economic value
CTCs provide in deciding on first-line
therapy.
HR+, HER2−MBC
patients
Randomized study where patients with
≥5 CTC/7.5 ml blood receive
chemotherapy and those with <5
CTC/7.5 ml receive endocrine therapy.
February 2015
COMETI P2
(NCT01701050)
Evaluating the algorithm CTC-Endocrine
Therapy Index (CTC-ETI) for the
identification of patients that will progress.
ER+, HER2−MBC
patients
ER, B-cell lymphoma-2 (BCL2), HER2, and
Ki-67 markers assessed on isolated CTCs
and CTC-ETI determined.
December 2015
Treat-CTC
(NCT01548677)
EBC, HER2− primary tumor patients with
no overt metastasis having completed
(neo) adjuvant chemotherapy and surgery.
HER2−, CTC+ EBC
patients
Patients randomized in 1:1 ratio to either
the trastuzumab arm or the observation
arm.
April 2017
CTC-CEC-AND
(NCT02220556)
Evaluation of different analysis methods
for CTCs, CECs, and circulating tumor
DNA in patient followed for a tumoral
pathology.
Patients with solid
tumors
Fifteen cohorts. Each cohort will test one
analysis method and/or tumoral type. Up
to 50 patients in each cohort.
December 2015
CirCe01
(NCT01349842)
Evaluation of the use of CTCs to guide
chemotherapy from the third-line of
chemotherapy for MBC.
Advanced MBC
patients
Patients with ≥5 CTCs/7.5 ml before
third-line of chemotherapy randomized
between CTC-driven and standard
treatment.
January 2018
DETECT III
(NCT01619111)
A multicenter, phase III study to compare
standard therapy±Lapatinib in HER2−
MBC patients with HER2+ CTCs.
HER2−MBC
patients with
HER2+ CTCs
Patients randomized between standard
therapy±Lapatinib. Patients with bone
metastases treated with denosumab.
March 2018
A large neoadjuvant chemotherapy study conducted by Rack
et al. (60) in EBC patients found separate prognostic importance
for the presence of CTCs pre- and post-treatment. Interestingly,
the initially CTC-negative patients who subsequently developed
CTCs fared better than initially CTC positive patients whose CTCs
disappeared post-treatment, suggesting CTC clearance does not
predict chemotherapy benefit (60).
To date, few studies have examined drug resistance in CTCs.
Gradilone et al. (97) evaluated CTC of 42 MBC patients for expres-
sion of multi-drug resistance-related proteins (MRPs) and/or
ALDH1, a putative tumor-initiating cell/CSC marker that corre-
lates with resistance to some chemotherapeutics. The expression
of MRPs on CTCs was found to be predictive of poor response
to chemotherapy and significantly correlated with reduced PFS
in MBC patients. Patients with CTCs expressing two or more
MRPs had shorter PFS than those with CTCs expressing zero or
one MRP (7.1 versus 16.4 months; p= 0.004). Furthermore, the
expression of ALDH1 on CTCs was correlated with MRPs (and
the number of MRPs expressed (p= 0.000) as well as an increased
resistance to chemotherapy. Gazzaniga et al. (98) screened 105
cancer patients (of which 14 had breast cancer) for CTCs and
then evaluated the MRP profile of the CTCs, postulating that this
could delineate chemotherapy responders from non-responders.
Patients were classified as chemotherapy “resistant” or “sensi-
tive” on the basis of their CTC MRP profile, together with the
chemotherapy regime the patient had received. This study found
that the MRP profiles of patients’ CTCs to be highly predictive of
response to chemotherapy, independent of tumor type and stage
of disease.
CONCLUSION
The presence of CTCs is a powerful independent prognostic factor
in both MBC and EBC. However, we increasingly understand that
CTCs are heterogeneous, even within an individual patient at dif-
ferent times in the disease trajectory (27, 99). This includes in the
receptors that they express, in relation to either the primary tumor
or any metastatic disease, as well as in their variable expression of
epithelial and mesenchymal markers.
Although CTC count changes are predictive of outcome in
MBC, this is largely a disease where serial agents are delivered
with palliative intent. Hence, early tailoring of therapies may not
greatly impact on outcome. To date, clinical trials have shown that
absolute CTC count alterations or CTC persistence do not pre-
dict strongly for neoadjuvant response, or improved adjuvant or
metastatic outcomes, and hence currently do not provide clini-
cally useful information to drive changes in therapies. With the
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maturation of the current clinical trials and further developments
in the molecular characterization of CTCs, this information will
hopefully become available.
Further work is needed, looking at CTC sub-populations
including the presence and importance of EMT and CSC popula-
tions, and their alteration with treatment. There may be potential
for targeting of otherwise treatment-resistant CTCs through novel
targets on such populations. Additionally, the appearance of estab-
lished therapeutic targets such as HER2 and ER on CTCs not
present on the primary tumor is of considerable clinical impor-
tance, and the results of ongoing HER2-targeting trials are awaited
with interest.
The promise of a “liquid biopsy” to diagnose, characterize,
monitor, and influence treatment of cancer is still some way off.
However profiling the presence and molecular characteristics of
CTCs is very likely to provide important predictive and prognos-
tic information in both early and MBC, and may prove useful in
assessing response to treatment and as an early warning system for
disease recurrence.
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